title: Inhibition of lipoprotein lipid oxidation.
abstract: According to the oxidative modification hypothesis, antioxidants that inhibit the oxidation of low-density lipoprotein (LDL) are expected to attenuate atherosclerosis, yet not all antioxidants that inhibit LDL oxidation in vitro inhibit disease in animal models of atherosclerosis. As with animal studies, a benefit with dietary supplements of antioxidants in general and vitamin E in particular was anticipated in humans, yet the overall outcome of large, randomized controlled studies has been disappointing. However, in recent years it has become clear that the role of vitamin E in LDL oxidation and the relationship between in vitro and in vivo inhibition of LDL oxidation are more complex than previously appreciated, and that oxidative events in addition to LDL oxidation in the extracellular space need to be considered in the context of an antioxidant as a therapeutic drug against atherosclerosis. This review focuses on some of these complexities, proposes a novel method to assess in vitro 'oxidizability' of lipoprotein lipids, and summarizes the present situation of development of antioxidant compounds as drugs against atherosclerosis and related cardiovascular disorders.
authors.affiliation: Fuji-Gotemba Research Laboratories, Chugai Pharmaceutical Co Ltd, Shizuoka, Japan.
authors.forename: O
authors.initials: O
authors.lastname: Cynshi
authors.forename: R
authors.initials: R
authors.lastname: Stocker
mesh_terms: D000818:Animals; D000975:Antioxidants / Q000627:therapeutic use; D050197:Atherosclerosis / Q000517:prevention & control*; D001572:Benzofurans / Q000627:therapeutic use*; D002318:Cardiovascular Diseases / Q000517:prevention & control; D006801:Humans; D008077:Lipoproteins, LDL / Q000378:metabolism*; D008315:Malondialdehyde / Q000032:analysis; D010084:Oxidation-Reduction; D011341:Probucol / Q000031:analogs & derivatives* / Q000627:therapeutic use; D017392:Thiobarbituric Acid Reactive Substances / Q000032:analysis
chemical_list: C106512:2,3-dihydro-5-hydroxy-2,2-dipentyl-4,6-di-tert-butylbenzofuran; D000975:Antioxidants; D001572:Benzofurans; D008077:Lipoproteins, LDL; D017392:Thiobarbituric Acid Reactive Substances; C099252:oxidized low density lipoprotein; D008315:Malondialdehyde; C471047:succinobucol; D011341:Probucol